NCT04831099View on ClinicalTrials.gov

Testosterone Treatment in a Patient With 17β-hydroxysteroid Dehydrogenase Type 3 Deficiency: an N-of-1 Study

PHASE3UnknownINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

July 26, 2022

Study Completion Date

July 26, 2022

Conditions
Disorder of Sex Development, 46,XY
Interventions
DRUG

Testosterone gel

The route of administration is transdermal.

DRUG

Placebo

The route of administration is transdermal

Trial Locations (1)

3015GD

Erasmus MC, Rotterdam

Sponsors
All Listed Sponsors
lead

Erasmus Medical Center

OTHER

NCT04831099 - Testosterone Treatment in a Patient With 17β-hydroxysteroid Dehydrogenase Type 3 Deficiency: an N-of-1 Study | Biotech Hunter | Biotech Hunter